Zomedica Corp. [AMEX: ZOM] price plunged by -7.79 percent to reach at -$0.01. The company report on November 13, 2020 that Zomedica Sets March 30, 2021 as Expected Commercialization Date for TRUFORMA™.
Certain assays under development are believed to be the first ever for use at the point-of-care and the first ever available in veterinary medicine.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that it expects to begin commercialization of its TRUFORMA™ point-of-care diagnostic platform on March 30, 2021.
A sum of 51755260 shares traded at recent session while its average daily volume was at 35.84M shares. Zomedica Corp. shares reached a high of $0.14 and dropped to a low of $0.13 until finishing in the latest session at $0.13.
The average equity rating for ZOM stock is currently 2.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Zomedica Corp. [ZOM]:
The Average True Range (ATR) for Zomedica Corp. is set at 0.01 The Price to Book ratio for the last quarter was 1.67, with the Price to Cash per share for the same quarter was set at 0.09.
ZOM Stock Performance Analysis:
Zomedica Corp. [ZOM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.37. With this latest performance, ZOM shares gained by 76.39% in over the last four-week period, additionally sinking by -18.08% over the last 6 months – not to mention a drop of -65.27% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 65.07, with the RSI for the last a single of trading hit 64.96, and the three-weeks RSI is set at 62.02 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.0916, while it was recorded at 0.1475 for the last single week of trading, and 0.1566 for the last 200 days.
Insight into Zomedica Corp. Fundamentals:
Return on Total Capital for ZOM is now -687.86, given the latest momentum, and Return on Invested Capital for the company is -687.85. Return on Equity for this stock declined to -687.85, with Return on Assets sitting at -387.30.
Reflecting on the efficiency of the workforce at the company, Zomedica Corp. [ZOM] managed to generate an average of -$706,573 per employee.Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 25.60 and a Current Ratio set at 25.60.
ZOM Stock EPS
With the latest financial reports released by the company, Zomedica Corp. posted -0.03/share EPS, while the average EPS was predicted by analysts to be reported at -0.02/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -50.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZOM.
Zomedica Corp. [ZOM] Insider Position Details
There are presently around $4 million, or 6.30% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. with ownership of 12,254,080, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 10,776,155 shares of the stock with an approximate value of $1.44 million in ZOM stocks shares; and MILLENNIUM MANAGEMENT LLC, currently with $0.39 million in ZOM stock with ownership of nearly 192.053% of the company’s market capitalization.
Positions in Zomedica Corp. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 23 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 9,857,776 shares. Additionally, 11 investors decreased positions by around 2,145,719 shares, while 5 investors held positions by with 20,617,461 shares. The mentioned changes placed institutional holdings at 32,620,956 shares, according to the latest SEC report filing. ZOM stock had 13 new institutional investments in for a total of 2,419,663 shares, while 9 institutional investors sold positions of 1,391,816 shares during the same period.